Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fauzia Riaz

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Current Opinion in Obstetrics & Gynecology|January 3, 2024
New strategies for the management of triple-negative breast cancerFauzia Riaz
Dermatology Nursing|January 28, 2010
Bullous pemphigoid: a short reviewBronwyn Southwell, Fauzia Riaz, Amor Khachemoune
Journal of the American Academy of Dermatology|August 21, 2010
Onychoheterotopia: pathogenesis, presentation, and management of ectopic nailFauzia Riaz, Rashid M Rashid, Amor Khachemoune
International Journal of Dermatology|December 11, 2013
Tinea versicolor in dark-skinned individualsJoseph R Kallini, Fauzia Riaz, Amor Khachemoune
Breast Cancer Research and Treatment|July 31, 2025
Impact of timing and breastfeeding on postpartum breast cancer diagnostic patterns and outcomesDaniella Klebaner, Natalie Park, Kimberly Stone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-EffectivenessJames C Dickerson, Jennifer L Caswell-Jin, Fauzia Riaz, et al.
JACC. Cardiooncology|March 6, 2023
Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for CancerSarah Waliany, Jennifer Caswell-Jin, Fauzia Riaz, et al.
JAMA Network Open|November 6, 2025
Molecularly Targeted Cancer Medications and Kidney HealthSusan Ziolkowski, Jin Long, Yutong Zhong, et al.
JAMA Oncology|November 4, 2021
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid CancersRavi B Parikh, Eun Jeong Min, E Paul Wileyto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2025
Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast CancerJames C Dickerson, Marcus T Moen, Perry Nielsen, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Opinion in Obstetrics & Gynecology|January 3, 2024
New strategies for the management of triple-negative breast cancerFauzia Riaz
Dermatology Nursing|January 28, 2010
Bullous pemphigoid: a short reviewBronwyn Southwell, Fauzia Riaz, Amor Khachemoune
Journal of the American Academy of Dermatology|August 21, 2010
Onychoheterotopia: pathogenesis, presentation, and management of ectopic nailFauzia Riaz, Rashid M Rashid, Amor Khachemoune
International Journal of Dermatology|December 11, 2013
Tinea versicolor in dark-skinned individualsJoseph R Kallini, Fauzia Riaz, Amor Khachemoune
Breast Cancer Research and Treatment|July 31, 2025
Impact of timing and breastfeeding on postpartum breast cancer diagnostic patterns and outcomesDaniella Klebaner, Natalie Park, Kimberly Stone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-EffectivenessJames C Dickerson, Jennifer L Caswell-Jin, Fauzia Riaz, et al.
JACC. Cardiooncology|March 6, 2023
Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for CancerSarah Waliany, Jennifer Caswell-Jin, Fauzia Riaz, et al.
JAMA Network Open|November 6, 2025
Molecularly Targeted Cancer Medications and Kidney HealthSusan Ziolkowski, Jin Long, Yutong Zhong, et al.
JAMA Oncology|November 4, 2021
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid CancersRavi B Parikh, Eun Jeong Min, E Paul Wileyto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2025
Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast CancerJames C Dickerson, Marcus T Moen, Perry Nielsen, et al.
Pageof 2